Abcam, ab269551, Human CD85d ELISA Kit (LILRB2)

Size: 1 x 96Tests
Human CD85d ELISA Kit (LILRB2) is a single-wash 90-min Simplestep used to quantify Human CD85d (LILRB2) with a sensitivity of 15.9 pg/ml. The assay uses a simple mix-wash-read protocol with just one incubation and one wash step. - Colorimetric Sandwich ELISA - 450 nm readout : works on any standard plate reader - Design your own immunoassay: we also offer the conjugation-ready antibody pair
Key facts
Detection method:Colorimetric,
Sample types:Heparin Plasma, Citrate plasma, Serum, EDTA Plasma,
Reacts with:Human,
Assay type:Sandwich (quantitative),
Sensitivity:= 15.9 pg/mL,
Range:62.5 - 4000 pg/mL,
Assay time:1h 30m,
Assay Platform:Pre-coated microplate (12 x 8 well strips)

Product details:
Human CD85d ELISA Kit (LILRB2) (ab269551) is a single-wash 90 min sandwich ELISA designed for the quantitative measurement of CD85d (LILRB2) protein in edta plasma, hep plasma, serum, and cit plasma. It uses our proprietary SimpleStep ELISA® technology. Quantitate Human CD85d (LILRB2) with 15.9 pg/ml sensitivity.
SimpleStep ELISA® technology employs capture antibodies conjugated to an affinity tag that is recognized by the monoclonal antibody used to coat our SimpleStep ELISA® plates. This approach to sandwich ELISA allows the formation of the antibody-analyte sandwich complex in a single step, significantly reducing assay time. See the SimpleStep ELISA® protocol summary in the image section for further details. Our SimpleStep ELISA® technology provides several benefits:
- Single-wash protocol reduces assay time to 90 minutes or less
- High sensitivity, specificity and reproducibility from superior antibodies
- Fully validated in biological samples
- 96-wells plate breakable into 12 x 8 wells strips
A 384-well SimpleStep ELISA® microplate (
ab203359
) is available to use as an alternative to the 96-well microplate provided with SimpleStep ELISA® kits.
CD85d (LILRB2), Leukocyte immunoglobulin-like receptor subfamily B member 2, is a key protein in the regulation of the immune response where it plays a pivotal as a negative regulator. It is primarily found on immune cells where it interacts with MHC domains on antigen presenting cells. Given its important role in immunosuppression, it is currently under investigation as a drug-targetable protein for a host of disease states. The antibodies for this kit were raised against a recombinant protein fragment targeting the extracellular domain of this receptor. There is little homology between mouse and rat for this fragment, so reactivity is not likely.

Properties and Storage Information:
Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
ILT-4 also known as Immunoglobulin-like transcript 4 is a transmembrane protein with a molecular weight of approximately 45 kDa. The protein is part of the LILR family and is sometimes referred to as LILRB2 protein. ILT-4 is mainly expressed on myeloid lineage cells including monocytes and dendritic cells. The expression of ILT-4 is important for the modulation of the immune response. Biotinylated ILT-4 and biotinylated LILRB2 versions are used frequently in research to study their interactions and functions.
Biological function summary
ILT-4 plays an important role in the regulation of immune tolerance and inhibition. It is not part of a complex but interacts with other immune regulatory proteins. By binding to MHC class I molecules ILT-4 inhibits the activation of immune responses preventing over-activation and autoimmunity. The ILT-4 protein is critical for helping myeloid cells to maintain a balanced immune response often restricting unnecessary inflammation and promoting tolerance.
Pathways
ILT-4 influences immune signaling pathways such as those that control T cell receptor signaling. ILT-4 interactions with proteins like CD85d and other LILRA6 proteins showcase its involvement in negative regulatory signaling pathways. These pathways are essential for maintaining immune homeostasis and limiting immune-mediated damage during infections or tissue injury.
ILT-4 is implicated in cancer and autoimmune diseases such as multiple sclerosis. In cancers ILT-4 modulates the immune environment allowing tumors to evade immune surveillance. In the context of autoimmune disorders aberrant ILT-4 expression or function can lead to insufficient immune regulation contributing to disease progression. CD85d and LILRB2 proteins are also associated with these conditions further influencing ILT-4's role in disease mechanisms.